Eqitx, Vaccine CRC join to take vaccine to market
21 January, 2004 by Melissa TrudingerPerth-based biotechnology company EqiTX (ASX:EQX) and the CRC for Vaccine Technology (CRC-VT) have joined forces to develop and commercialise the CRC's lipopeptide vaccine technology.
BioDiem to float next week after IPO success
21 January, 2004 by Melissa TrudingerBioDiem is looking forward to floating on the ASX on January 27, after successfully raising AUD$8.5 million through an IPO.
BioDiem gets a sniff of $50 million 'flu vaccine fund
19 December, 2003 by Graeme O'NeillIn the middle of its AUD$10 million float, Melbourne pharmaceutical development company BioDiem has been buoyed by news that the US Food and Drug Administration has allocated $US50 million to boost production of influenza vaccines, which are in chronically short supply in North America.
Funding starts to flow for stem cell projects
18 December, 2003 by Melissa TrudingerAlmost exactly a year after the federal government named the National Stem Cell Centre (NSCC) as Australia's biotechnology centre of excellence, the first round of funding has been distributed to researchers at six institutions across Australia.
Virax takes hep B compound into pre-clinical phase
12 December, 2003 by Melissa TrudingerMelbourne therapeutic vaccine company Virax (ASX:VHL) has taken its hepatitis B treatment into the pre-clinical development phase.
QUT team develops rapid staph test
01 December, 2003 by Graeme O'NeillA Queensland research team has developed the world's first rapid DNA test to identify methicillin resistant Staphylococcus aureus (MRSA).
Peplin Biotech acquires omega-3 portfolio
24 November, 2003 by Melissa TrudingerBrisbane-based Peplin Biotech has acquired a portfolio of synthetic engineered polyunsaturated fatty acid compounds from researchers at Adelaide's Women's and Children's Hospital in a deal worth AUD$225,000 plus shares and options worth around $350,000.
Blair backs biotech plan for more UK drug trials
18 November, 2003 by Ben HirschlerBritish Prime Minister Tony Blair said the government would provide £10 million (AUD$16.9 million) to study ways to get more experimental medicines to patients through better and faster clinical trials.
EQiTX to develop vaccine technology platform
17 November, 2003 by Melissa TrudingerPerth-based biotechnology company EQiTX and the CRC for Vaccine Technologies have negotiated an agreement for EQiTX to develop and commercialise the CRC's proprietary lipopeptide vaccine technology platform.
Big pharma said to be testing Select's Hep A vaccine
12 November, 2003 by Melissa TrudingerA number of multinational pharmaceutical and biotechnology companies from Europe, the US and the Asia-Pacific are evaluating Select Vaccine's rapid diagnostic hepatitis A kit as a forerunner to license negotiations, the company (ASX:SLT) said on Tuesday.
Norwood in lucrative deal with US pharma
11 November, 2003 by Melissa TrudingerNorwood Abbey (ASX: NAL) has entered into a lucrative deal with TAP Pharmaceuticals, giving the US-based company an exclusive license to commercialise its immunology intellectual property in the US market.
Primitive microbe lends a hand to high-tech crime fight
07 November, 2003 by Graeme O'NeillA steaming, sulphurous spring in the caldera of the world's coldest, most isolated volcano has yielded a powerful new forensic tool that will make it even tougher for criminals to evade the law.
Stem cell research: Retinal cells could be first to clinic
31 October, 2003 by Melissa TrudingerRetinal stem cells could well be the first neural stem cells used in patients, University of Toronto researcher Derek van der Kooy predicted recently at the National Stem Cell Centre conference in Melbourne.
Stem cell research: Turning sugar into bone
31 October, 2003 by Melissa TrudingerUniversity of Queensland scientist Assoc Prof Victor Nurcombe has moved to Singapore to continue his work on repairing bone fractures using sugars from the surface of cells.
Stem cell research: the big task ahead
31 October, 2003 by Melissa TrudingerIn his closing comments to the National Stem Cell Centre conference in Melbourne earlier this month, Monash University's Martin Pera gave voice to a thought many of the scientists at the conference had been contemplating over the previous couple of days. "What is in front of us is of the scale of the Human Genome Project, if not larger," Pera told delegates. "In the last five years the ethical frameworks have been established. But we have to continue the ethical debate."
